Rebel
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“And send it to the lab...”. Key word is SEND. See? That is what Arrayit does and is now doing and will be doing for a very long time. In-home testing will be next, imho.
Smart investors know that VERY OFTEN investors find that their shares were acquired at a lower price than their bid, and those go on the SELL side when they are, in fact, BUYS.
Smart investors also know that down here in the valley, day traders and flippers like to party. So they flip for their beer money. Smart investors also know that they will eventually flip themselves out of a stock, a happy thing.
Smart investors further know all about manipulation games and other mysterious happenings that are made to discourage investors from holding onto their shares.
Das right.
Nope. You see, the CRADA with USDA doesn't end until February 24, 2021! Research Project: Molecular Identification and characterization of Bacterial and Viral Pathogens Associated with Foods
Location: Produce Safety and Microbiology Research
Project Number: 2030-42000-051-00-D
Project Type: In-House Appropriated
Start Date: Feb 25, 2016
End Date: Feb 24, 2021
Objective:
The overall objective of this project is to develop novel typing methods to identify foodborne pathogens and characterize: bacterial foodborne pathogens through genomics, transcriptomics and proteomics; virulence factors and bacterial toxins; and antibiotic resistance in food production. Specifically, during the next five years we will focus on the following objectives: Objective 1: Develop improved identification technologies for human bacterial and viral pathogens to replace current testing methodologies. Sub-objective 1A: Develop a fast, simple and high throughput array-based method fortyping pathogens. Sub-objective 1B: Validate the array genotyping tool for the identification of viral and bacterial pathogens in samples from agricultural environments. Sub-objective 1C: Develop novel Campylobacteraceae species identification methods. Objective 2: Identify and characterize genetic factors associated with virulence and/or environmental adaptation of human bacterial pathogens using genomic, transcriptional and proteomic analyses. Sub-objective 2A: Identify the transcriptional network patterns of bacterial pathogens during environmental adaptation and modulation of their stress response. Sub-objective 2B: Identify genes involved in host/environmental adaptation and investigate variation in virulence potential through in-depth genome sequencing of selected taxa. Sub-objective 2C: Identify the genetic and epigenetic alterations or factors involved in the environmental adaptation of foodborne pathogens through genomic and methylome analyses. Sub-objective 2D: Quantitative proteomic and transcriptomic analysis of virulence factors of foodborne pathogens can be used to elucidate transcriptional vs. posttranscriptional control of virulence in foodborne pathogens. Sub-objective 2E: Top-down proteomic characterization of bacterial virulence proteins or toxins. Objective 3: Characterize molecular mechanisms contributing to the potency of bacterial toxins. Sub-objective 3A: Identification and characterization of Shiga toxin 2 (Stx2) subtypes in environmental STEC strains. Sub-objective 3B: Characterization of Stx2 expression levels and functional activities in environmental STEC strains. Sub-objective 3C: Characterization of pathogenic mechanisms associated with Stx2 subtypes produced by E. coli strains. Sub-objective 3D: Investigate toxin-inactivation mechanisms by natural plant compounds. Objective 4: Identify antimicrobial resistance gene reservoirs in the food production ecosystem and characterize the fitness and virulence of resistant pathogens. Sub-objective 4A: Complete genomic sequencing and functional metagenomic analyses of antibiotic-resistant Campylobacter. Sub-objective 4B: Characterization of the fitness and virulence of antimicrobial-resistant Campylobacter jejuni and Campylobacter coli.
Approach:
Objective 1: A fast, simple and high throughput array-based method for typing pathogens will be developed. Capture probes will be designed to target norovirus and hepatitis A virus, clinically-important Salmonella serovars and Campylobacter spp. To evaluate probe specificity, viral RNA or bacterial DNA will be extracted from clinical samples or cultured strains. A Cooperative Research and Development Agreement (CRADA) has been established with Arrayit Corporation to develop a fast, simple, and cost-effective test, in conjunction with inexpensive instrumentation. The array genotyping method will be validated using samples from agricultural environments. Also, MALDI-TOF-MS will be assessed as a faster, more accurate and reliable identification of Campylobacteraceae taxa, when compared to current phenotype-based approaches. Objective 2: The transcriptomic patterns that correlate with environmental adaptation and stress modulation for Campylobacter, Salmonella and E. coli will be determined, using RNA-Seq under distinct and relevant environmental conditions. Gene content or alleles that tentatively correlate with niche preference, environmental adaptation or pathogenicity will be identified by sequencing Campylobacter and Arcobacter isolates from a more diverse strain set. Alleles or methylation patterns within a population that correlate with environmental adaptation or pathogenicity will be identified through next-generation genomic analysis. Also, proteomic and transcriptomic analysis will be used to investigate transcriptional/post-transcriptional control of virulence factors and to characterize bacterial toxins and virulence determinants. Objective 3: A genotypic and proteomic screen for identifying and classifying Shiga toxin subtypes, harbored by strains recovered from different sources and locations in a major agricultural region, will be conducted. Using enzyme-linked immunosorbent assay and cell-based assays, the amounts and functional activities of Shiga toxin 2a and 2c subtypes will be determined. Using surface plasmon resonance, the mechanisms contributing to the cytotoxicities associated with the Shiga toxin 2a and 2c subtypes will be characterized, by investigating their role in the inhibition of protein synthesis in mammalian cells, thus providing a better understanding of the toxin’s mode of action. Natural plant compounds, specifically polyphenolics, will be investigated as potential inactivators of bacterial toxins. Objective 4: Genome sequencing of antimicrobial-resistant Campylobacter, isolated from poultry farms, will be performed to identify (potentially novel) antibiotic resistance genes. Metagenomic analysis of bacteria isolated from samples (such as litter, insects and fecal droppings) from these same poultry farms will be performed to identify the pool of ‘available’ antibiotic resistance genes that could potentially be transferred into Campylobacter. The fitness and virulence of resistant Campylobacter will be measured, to determine if increased fitness explains the persistence of resistant strains. Fitness metrics will include survival in insects and on poultry, and fecal colonization.
Return to topLast Modified: 03/31/20
https://www.ars.usda.gov/research/project/?accnNo=430420
Well look at that: "ALLERGY and COVID-19 LOGIN." I wonder how many COVID-19 tests they've done so far and/or how many they can add to the 50,000 requests from a week or two ago, which requests I assume were from Arrayit's already established and large client base of doctors, clinics, and other health care professionals.
The only one who doesn't think Mark should have an automobile is you.
Do you not understand that test is NOT what Arrayit does, nor is it the cure-all of COVID-19 testing? Arrayit's test will give more comprehensive information at a much faster rate, but it is NOT a test that can be done at the point of care.
Good grief.
Nobody said it was news and it's certainly not "horrible," That test is not what ARYC does. It's a point-of-care test for hospital personnel, etc. Arrayit's COVID-19 testing is much more comprehensive. Pinner USA is a marketing consultant and having them as one of ARYC's partners is not a bad thing and in no way a "horrible" thing.
Oh the drama!
Happy for you, SD. Fill that boat!
:))
It says that you do not understand. Pinner USA is listed as a "marketing consulting" company. Don't know what is "extremely questionable," do you?
CLIA Certified Laboratory
23 Years of Experience
Arrayit Corporation was founded in 1993 by Rene Schena and Todd Martinsky as TeleChem International Inc, as a life sciences company. After several years of successful revenue growth, the company expanded in 1999 by adding Dr. Mark Schena and Paul Haje, who together with Ms. Schena and Mr. Martinsky, founded Arrayit Life Sciences, a division of TeleChem International, Inc
Hundreds of Patents and Various Awards
Since 1999, Arrayit has built a powerful portfolio of patents, trade secrets, and more than 650 life sciences products. The company was featured on the TV series NOVA, “Cracking the Code of Life”, by PBS with Mr. Mark Schena, received successive appointments to the Inc. 500 list, and has received numerous local awards including the Rising Star Award and the Silicon Valley 50 Award. The company changed its name to Arrayit Corporation and began trading on the OTC Bulletin Board in 2009 as ticker symbol ARYC. Arrayit located to its new company headquarters in Sunnyvale in 2013. The company’s products and services are used in the life sciences, pharmaceutical, and diagnostics markets Worldwide.
CLIA Number: 05D2147467
https://pinnertest.com/
If you don't believe it, then please do your DD. It's all out there in cyberspace and not that hard to find. Arrayit DOES HAVE a COVID-19 test! Believe it or not.
lol.
Arrayit's test should be able to do exactly that (test those who have recovered), and they can do it at top speed!
Coronavirus serological tests: Tracking exposure
"Beyond detecting active infections, getting a handle on the pandemic will require tests that can detect anyone who has ever been exposed to SARS-CoV-2 — even if they fought it off without showing symptoms. These tests, called serological tests, search the blood for antibodies to the virus.
Knowing who has already been infected is important for three reasons, Kroll said. One, health care workers who have been exposed and likely have immunity can go to work with less fear, and perhaps use less PPE than those who have not been exposed. That could help ease the strain on scarce PPE supplies, Kroll told Live Science. In addition, by testing the general population, individuals may be able to ease their social-distancing routine and even go back to work first once stay-at-home orders ease. Finally, those who have been sick might be able to help cure those who are severely ill.
"Serology could potentially be used to identify people who have protective immunity that could help other people," Pritt said.
It's called convalescent plasma treatment, and it works on a simple principle: Those who have fought off the infection have antibodies in their blood that helps the immune system take down SARS-CoV-2. These antibodies can be isolated from the blood of recovered patients and then injected into patients who are ill. The hope is that the antibodies will start stimulating the sick patients' immune systems to better fight the disease. This treatment is now being tested in New York City."
https://www.livescience.com/coronavirus-tests-available.html
You're welcome. :))
That is no surprise since Arrayit's equipment and supplies are all over this world.
As Arrayit's long-time partner, Pinner USA may be in need of ARYC's services in some capacity...I mean their partnership is not a bad thing!
It's a point-of-care test done at the premises.
ARYC's partner (Pinner USA/Pinnertest) is now in the loop.
https://www.cbs19news.com/story/41954664/pinner-c9-covid19-finger-prick-blood-test-results-in-minutes
Good for you, but many have made buckets of money already and are looking forward to multi dollar-land this time around.
So do I. Honest people are hard to come by around these parts. Very sad.
Poof.
Lol. Whatever.
If you don’t believe what has come out of the company, then that’s your personal problem. I know what I know and it’s all good.
No, you didn’t ask me. Just trying to save SD from wasting his precious time.
You know what they are or you wouldn’t be here 24/7. I don’t have to answer to you.
Look it up.
Yes you do. There would be no other reason for you to be here.
I think you know of their accomplishments or you wouldn’t be here.
I know, but they will say ANYTHING, true or not, to try to get people to sell their shares.
We know who the true winners will be here at ARYC!
What I said in my post is 100% correct.
You and others kept saying that ARYC is currently dumping shares into the market and diluting and that is 100% false. I wasn't referring to the dilution that happened almost 5 years ago. My post should not have confused you or anyone, even a little bit.
No thank you. Not going to waste my time.
Just in time - 8:49 a.m. right now in Sunnyvale. Open for business!
:))
So this your focus, most of which is untrue and/or distorted, while the entire world is suffering and with so many innocent people dying from the coronavirus? Why not focus on ARYC's microarray technology and their COVID-19 testing that will help to shut down the beast, rather than all of this meaningless gobbledygook that nobody believes.
This is 2020, NOT 2015 and it is obvious you have NO CLUE as to the reasons behind the dilution, and it has nothing to do with automobiles or pie.
So sad.
It’s there and under construction. See my last post.
It looks like they’re joining the HIPAA compliant cloud. “Patient DataSolutions.com-we’re just getting ready - check back soon.”
That's it of course, and that is called stock manipulation and it is illegal.
:))
There is nothing planned for April 1st unless you have a link to prove otherwise.
Call the TA. No dilution.
lololol. No dilution in five years! Think! Put the pieces together as to why the dilution happened five years ago. To say that Mark sold those shares to put money in his own pocket is totally wrong.
There were specific reasons behind why the company HAD to do it. Good luck with your research.
Exactly! And it's not hard to tell them apart: Truth - IGNORANCE.
Easy peasy.
I think anyone who made it past the third grade can figure out what is true and what is not true on this board, and if they have any questions, they will know that they should ask those who are knowledgeable about ARYC because it's so obvious.
:))